Estimates of the costs associated with cancer care are essential both for assessing burden of disease at the population level and for conducting economic evaluations of interventions to prevent, detect, or treat cancer. Comparisons of cancer costs between health systems and across countries can improve understanding of the economic consequences of different health-care policies and programs. We conducted a structured review of the published literature on colorectal cancer (CRC) costs, including direct medical, direct nonmedical (ie, patient and caregiver time, travel), and productivity losses. We used MEDLINE to identify English language articles published between 2000 and 2010 and found 55 studies. The majority were conducted in the United States (52.7%), followed by France (12.7%), Canada (10.9%), the United Kingdom (9.1%), and other countries (9.1%). Almost 90% of studies estimated direct medical costs, but few studies estimated patient or caregiver time costs or productivity losses associated with CRC. Within a country, we found significant heterogeneity across the studies in populations examined, health-care delivery settings, methods for identifying incident and prevalent patients, types of medical services included, and analyses. Consequently, findings from studies with seemingly the same objective (eg, costs of chemotherapy in year following CRC diagnosis) are difficult to compare. Across countries, aggregate and patient-level estimates vary in so many respects that they are almost impossible to compare. Our findings suggest that valid cost comparisons should be based on studies with explicit standardization of populations, services, measures of costs, and methods with the goal of comparability within or between health systems or countries. Expected increases in CRC prevalence and costs in the future highlight the importance of such studies for informing health-care policy and program planning. Estimates of the costs associated with cancer care are essential both for assessing burden of disease at the population level and for conducting economic evaluations of health-care policies and programs to prevent, detect, or treat cancer. Although considerable methodological progress has been made in disease costing (1), significant challenges remain. Importantly, existing data for cost determination in any given study are generally imperfect, sometimes missing, and often collected or analyzed in ways that make cross-study comparisons difficult. An underlying problem is that available data sources were generally created for other purposes (eg, paying bills) and are substantially influenced by features of the health-care system, including the structure of insurance plans and databases for tracking care (2). The alternative approach of collecting precisely the resource use data needed for a given economic evaluation can be expensive and time-consuming in practice, and there is wide variation in these "microcosting" studies (3).
Estimates of the costs associated with cancer care are essential both for assessing burden of disease at the population level and for conducting economic evaluations of health-care policies and programs to prevent, detect, or treat cancer. Although considerable methodological progress has been made in disease costing (1), significant challenges remain. Importantly, existing data for cost determination in any given study are generally imperfect, sometimes missing, and often collected or analyzed in ways that make cross-study comparisons difficult. An underlying problem is that available data sources were generally created for other purposes (eg, paying bills) and are substantially influenced by features of the health-care system, including the structure of insurance plans and databases for tracking care (2) . The alternative approach of collecting precisely the resource use data needed for a given economic evaluation can be expensive and time-consuming in practice, and there is wide variation in these "microcosting" studies (3) .
Thus, even within a single health system or country, studies with an identical purpose (eg, estimating the costs of chemotherapy in the year following cancer diagnosis) frequently use different methods, with data sources that vary in scope, population coverage, completeness, and capacity to examine patterns of service use. Internationally there is tremendous diversity in health-care systems, services covered, and availability of existing data sources relevant to health-care costing (4,5)-making comparisons of cancer costs across countries all the more difficult. Despite these challenges, comparisons within and between health systems and countries can enhance understanding of the economic consequences of differences in policies related to cancer care, as well as broader health-care programs, such as a coordinated hospice program for end-of-life care. Understanding the extent to which studies can be compared is also critical for economic evaluations of cancer prevention, screening, or treatment interventions, which may synthesize estimates from multiple sources as inputs to cost-effectiveness models.
In this paper, we investigate the implications of this diversity in methods, health systems, and data sources for cost analyses through a structured review of the published literature on the economic burden associated with colorectal cancer (CRC) care. Worldwide approximately 2.1 million individuals were newly diagnosed with CRC in 2008, and CRC is the second most common cancer in women and the third most common in men (6) . CRC prevalence is expected to increase appreciably in most developed countries as a result of population growth and aging, because CRC incidence increases with age (7) . Additionally, ongoing efforts to improve early detection and treatment are expected to improve CRC survival and reduce CRC-related mortality, which will also result in increasing disease prevalence.
Consequently, the societal burden of CRC is significant and is likely to increase over time (8, 9) . Important economic components of this burden include direct medical care costs, direct nonmedical costs (such as patient time involved with receiving medical care),
Data Abstraction
Data were abstracted from each paper using a standardized abstraction format to describe the study characteristics, cancer patient characteristics, and study methods. Study characteristics included study publication year, country where study was conducted, geographic setting (single city, single state/province/region, multiple cities and/or states/provinces/regions, national, multiple countries), delivery setting (single institution or clinic, network of institutions or clinics, integrated system/insurance network, other), and the type of cost estimate evaluated (direct medical, direct nonmedical, including patient or caregiver time and travel, and productivity loss). Because health-care delivery in the United States is fragmented, we also abstracted information about the type of health insurance (feefor-service, managed care, multiple types of insurance) and measurement of cost (insurance payments only, patient out-of-pocket payments, charges). Cancer patient characteristics included method of patient identification (medical record review, registry, claims, other), tumor stage (American Joint Committee on Cancer [AJCC] I/II or localized, AJCC III/IV or regional/distant, other, stage not reported), number of cancer patients (100-499, 500-999, 1000-4999, 5000-9999, 10 000+) and patient age groups (<40, 40-64, 65+, mean age <65, mean age 65+, patient age not stated).
Study methods that were abstracted included study design (crosssectional, cohort, based on a randomized controlled trial), phases of care evaluated (initial treatment, surveillance or continuing, last year of life, long-term/lifetime, all phases together [prevalent] , other), use of a comparison group (noncancer controls, other comparison group, no comparison group), and use of price adjusters (time adjusters, other adjusters, not reported).
Medical cost estimates for prevalent CRC patients (both incident and existing patients) were abstracted separately at the perperson and aggregate levels. Medical cost estimates were also abstracted separately for each phase of care. Studies that could not clearly define patients with incident disease, or that identified patients with metastatic disease but did not distinguish newly diagnosed from recurrent disease, or that were based on receipt of specific treatment, were classified as cost estimates of prevalent cancer patients. Studies based on patterns of care observed in clinical trials of cancer treatment were abstracted separately, as were studies of other aspects of the burden of illness, including patient and caregiver time and productivity loss.
Consistent with the diverse approaches found in the literature, we use the term "cost" broadly to reflect either expenditures, insurance payments, charges, actual costs of care, or wages, and we abstracted data as reported in the underlying studies. The "reference year" used to adjust for monetary inflation (eg, in 2000 dollars) was abstracted as reported, or noted as not reported when the reference year was not available in the underlying study. We did not attempt to standardize studies to a single reference year, because it would not be meaningful to do so given the heterogeneity across health systems and countries in cancer care delivery settings, data sources, patient populations, measurement of cost, types of medical services, use of comparison groups, and other methodological differences. Finally, findings are reported as either total costs or cancer-related costs. Total costs reflect the cost of all services received by cancer patients. Cancer-related costs reflect either the cost of services presumed to be related to cancer treatment or else the net cost of all services among cancer patients compared with similar individuals without cancer. Nonmedical costs are also reported as either total or cancer-related based on comparisons with similar individuals without cancer.
Results

Study Characteristics
The number of published studies of the costs of CRC care increased throughout the study period, with almost half being published between 2008 and 2010 ( Table 1) . The majority of studies were conducted in the United States (52.7%), followed by France (12.7%), Canada (9.1%), and the United Kingdom (9.1%). Studies were also conducted in Brazil, Germany, Greece, Hungary, Italy, Japan, and Norway. Almost 90% of studies estimated direct medical costs, and few estimated patient or caregiver time costs (14.5%), travel costs (7.3%), or productivity losses (7.3%). In the United States, the dominant health insurance type was fee-forservice, with few studies conducted in managed care or across multiple types of payers/providers. The most commonly used data source was the linked SEER-Medicare data, which include only fee-for-service insurance predominantly for patients aged 65 and older. Studies varied in the comprehensiveness of estimates, 65 and older, either because they included patients of all ages and CRC incidence was higher in the elderly, or because they were conducted in the United States using SEER-Medicare data. Age was not stated in seven studies.
Of the 55 studies included in the review, 32.7% were crosssectional, 43.6% were conducted in observational cohorts, and 25.5% were clinical trial-based. The majority of observational studies were conducted in the United States, whereas the majority of clinical trial-based studies were conducted in other countries. Many studies assessed the costs of CRC in prevalent samples of patients (40%), including clinical trial-based studies of treatment for metastatic disease. Many observational studies assessed either costs of initial treatment of incident disease or the initial phase of care (34.5%), or long-term/lifetime costs (23.6%), or both. Fewer observational studies assessed care at the end of life (18.8%). About one-third of the studies did not include a comparison group. Most studies used inflation price adjusters to standardize costs over the study period, but a sizable portion did not report use of any price adjusters (27.3%).
Direct Medical Costs of CRC Care in Observational Studies
National estimates of the direct medical costs of CRC were conducted in France, the United States, Canada, Brazil, and Hungary (20, 30, 31, 34, 39, 66, 69) (Table 2 ). Estimates were for either the entire population with cancer in a given year or for a subset of newly diagnosed patients in a given year over some defined time period, ranging from the first year following cancer diagnosis up to the patient's lifetime. Although several studies included the entire population of CRC patients, others were restricted to only the elderly. Finally, the scope of care included in these estimates varied widely-one study included only hospitalizations, whereas others included all care following diagnosis.
Ten studies estimated the cost of cancer care in prevalent patients, the combination of newly diagnosed and existing cancer patients (17, 19, 21, 27, 36, 42, 54, 57, 63, 70) (Table 3 ). These studies were conducted exclusively in the United States, but the number of patients, age distribution, data source, types of costs included, and reference year varied widely. For example, two studies assessed ambulatory care, but one reported cancer-related costs for chemotherapy ranging from $1028 to $38 027 for different regimens (57) , and the other reported payments for all care of $946 among individuals with cancer (27) . Neither reported the year of dollars, patient age distribution, or period during which costs were accrued.
Fourteen studies assessed the costs of CRC care by phase of cancer care (Table 4) , including 10 in the initial phase or initial care period (16, 18, 31, 32, 34, 39, 41, 48, 55, 67) , five in the continuing phase (16, 24, 34, 41, 66) , and five in the last year of life (16, 29, 34, 41, 58) . The majority of these studies were conducted in the United States, with three in France and one each in Canada and Norway. There was notable variation across studies in the number of patients, age distribution, definition of phase, type of costs, and reference year. For example, even among the US studies using the SEER-Medicare linked data for patients aged 65 and older, estimates ranged from mean cancer-related costs in 12 months of the initial phase of $29 609 in men and $29 930 in women in 2004 dollars (34) to total costs of $41 134 in the first year following diagnosis in 2003 dollars (31) . The latter study reported total costs incurred by those diagnosed with CRC, whereas the former estimated cancer-related costs. These studies also differed in the calendar years of observation and definitions of the initial period of treatment (12 months following diagnosis vs initial phase of care).
Eleven studies reported long-term or lifetime costs associated with CRC care (16, 22, 23, 34, (38) (39) (40) (41) 59, 62, 68) (Table 5) . Again, studies were conducted predominantly in the United States, with two in Canada and one each in the United Kingdom and France, and varied substantially in the samples, settings, types of care and costs included, and time periods covered postdiagnosis (eg, 2 years, 6-11 years, 25 years, lifetime). Despite these differences, lifetime cancer-related costs were generally higher in younger patients compared with older patients, as might be expected (16) . Additionally, costs were generally higher among patients with more advanced disease at diagnosis (39), although lifetime costs were lower in (Table 6 ). Studies were conducted mainly outside of the United States, in the United Kingdom, France, Italy, Japan, Germany, and Greece. These studies generally measured patterns of care during the period of the trial and applied standardized cost multipliers to the services and procedures observed to estimate patient-level costs. Several studies were multinational and estimated costs for a single country based on all patients in the trial (across countries), whereas others were single-country trials and yielded cost estimates for that country only. Even though the majority of studies reviewed here assessed chemotherapy, and most evaluated metastatic disease, there was significant variability in the choice of comparators, period of evaluation, types of costs included, and level of detail reported.
Nonmedical Costs of CRC Care
Ten studies estimated patient or caregiver time costs or productivity loss associated with cancer (21,25,28,33,56,60,61,64,69,73) ( Table 7) . Studies were conducted in the United States, Canada, France, and the United Kingdom. Nine were observational studies and one was conducted among a subset of patients from a clinical trial. As in the studies of medical costs associated with CRC care, there was wide variation in the methods for identifying patients or caregivers, components of time or productivity measured, evaluation periods, and approaches for valuing time or lost productivity. Standard approaches for estimating time costs or productivity loss combine wage rates or other measures of the value of time with measures of time, either as self-reported by patients or caregivers through surveys or else derived empirically from medical care utilization data combined with standard service-specific time estimates or actual sick leave records. There was, however, significant variation observed within this general approach. For example, one study surveyed elderly individuals and asked about the number of hours in a recent week they required informal care and compared estimates for those with and without a self-reported diagnosis of cancer (61) . Another study of informal caregiving used registries to identify newly diagnosed cancer patients, who then identified a caregiver who was surveyed about the amount of time they had provided informal care to the patient in the years following cancer diagnosis (56) .
Discussion
In this study, we conducted a systematic review of recently published studies of the economic burden associated with CRC care to assess data, methods, scope, and the extent to which estimates from these studies can be used in "head-to-head" comparisons. As might be expected, the economic cost associated with CRC care within study generally varied by stage(s) of disease at diagnosis, patient age, observation time (eg, 12 months following diagnosis vs lifetime), types of medical services included, and the scope of costs considered. Depending on the study, included costs ranged from single components of medical care only (eg, hospitalizations) to more comprehensive economic measures of resource use that might include patient time, travel for care, and productivity losses associated with cancer and its treatment. Even within country, we found great heterogeneity across studies in the settings, data sources, populations, means of patient identification, types of medical services, and study methods. Each of these study characteristics can significantly influence the estimation of cancer costs. When they vary together across studies, as is typically the case, even cost calculations with seemingly the same objective are difficult to compare. Complicating factors include features of the healthcare delivery system, accompanying payer model, and data availability, all of which vary by country. Across countries, published aggregate and patient-level cost estimates vary in so many respects that accurate international comparisons are almost impossible. Our findings suggest that valid cost comparisons must be developed de novo with explicit standardization of patient populations, types of medical services included, measures of cost, and choice of methods, whether the context is within or between health systems or countries. Further, the design of such studies should reflect a detailed understanding of health-system payment and reimbursement policies and their impact on available data (74, 75) . Despite these challenges, improving our understanding of how best to measure and report the economic burden of cancer is critical because the aggregate economic burden of cancer, including direct medical costs, direct nonmedical costs, and productivity losses, is expected to increase in the future (8, 9, 76) . To improve comparability across studies, we need more detailed reporting of patient characteristics, methods, and cost estimates by patient subgroups associated with the cost of care (eg, age, stage at diagnosis), the setting of care (eg, inpatient hospitalizations), and the type of cancerrelated service (eg, chemotherapy) in both newly diagnosed and prevalent samples. Additionally, because variation in cancer prevalence and population sizes across countries limits national comparisons, reporting of per-person estimates by age, health-care setting, and components of care will allow better national comparisons.
Expected increases in the burden of cancer highlight the importance of evaluating the transferability and economic consequences of effective care delivery and payment models used in other healthcare delivery settings and countries. A key component of this rising cost burden is the growing use of more effective, but dramatically more expensive cancer treatments. Cost-effectiveness analyses of alternative cancer treatment interventions clearly require sound estimates of each intervention's associated costs, as well as its benefits in terms of survival or health-related quality of life. Moreover, when cost-effectiveness analyses are focused on cancer prevention or screening, the cost of cancer care is still a pivotal input. Specifically, to prevent or delay the onset of a cancer, or to detect it at an earlier stage, is to alter the expected lifetime cost profile of cancer treatment for the individual. Changes in the costs and benefits of CRC treatments also necessarily affect the cost-effectiveness of cancer prevention and screening strategies (77) , such that they may become either more or less cost-effective, or even cost-saving. Updating these analyses to reflect changes in CRC costs and benefits may impact policies in countries that use cost-effectiveness to inform formulary policy decisions. Increased standardization of methods to estimate the economic burden of cancer over time, conditional on choice of intervention, can improve the comparability and consistency of information for setting priorities among competing cancer control interventions (76) .
The majority of studies we reviewed included just one component of the burden of cancer-direct medical care costs. Fewer studies assessed costs associated with patient and caregiver time or productivity losses associated with cancer and its treatment, (80) and increased use of sick leave among spouses (81) , although these studies did not quantify the impact on employment in economic terms. Thus, to strengthen the data available for estimating the nonmedical economic burden of cancer, increased attention should be devoted to linking data on cancer incidence and survival with longitudinal information on labor market participation and earnings and the allocation of time to medical care-related activities and, in parallel, to developing additional sources of information on the nonmedical burden of cancer. These could include targeted enhancements to existing population-based surveys, such as the Medical Expenditure Panel Survey Experiences with Cancer Survivorship Supplement in the United States (82) . Developing a more comprehensive picture of the economic burden of cancer for the patient and family could inform decisions in the workplace. In particular, these data can be important for employers interested in minimizing the impact of cancer on patient and caregiver employment outcomes, including presenteeism and workplace productivity, absenteeism, and overall retention. Including other components of the burden of cancer, such as patient time costs, caregiver burden, and productivity losses, will improve our understanding of the societal impact of cancer and may inform further development of employment policies.
We observed clearly discernible relationships between the country where a study was performed, study design, and the approaches used for estimating either the prevalence or incidence cost of care. The majority of US studies were observational, whereas the majority of studies in other countries were based on clinical trials focusing on the cost or cost-effectiveness of treatment interventions, presumably to inform coverage decisions by national formularies (ie, NICE) or other purchasers. Other differences in health-care systems, and hence the nature of the data available for cost analyses, influenced the types of studies conducted. For example, the majority of CRC cost studies in the United States were conducted among patients aged 65 and older, using the linked SEER registry-Medicare claims data. By implication, very few studies were conducted in the under-65 population, which leaves an important research gap because cancer care is typically more aggressive in younger compared with older patients within stage at diagnosis (83) . In addition, the difference in comorbidity between cancer patients and noncancer controls is greater in the under-65 population compared with the elderly. In the United States, information about health-care use and payments is available primarily from health insurance claims, and the largest population with comprehensive and longitudinal claims and enrollment information currently consists of Medicare enrollees, aged 65 and older. Current efforts to estimate the longitudinal costs of CRC care for patients of all ages in the managed care population and state-based efforts to link population-based cancer registry with multiple public and private claims databases may help address these important data gaps (84) (85) (86) .
The studies based on clinical trials used service frequencies collected as part of the trial, and actual costs or standardized servicespecific costs that were then applied to service use, to estimate CRC treatment costs. An important advantage of this microcosting approach is that it allows country-specific and importantly comparable estimates to be generated from multinational trials. Also, cost estimates are based on actual care received, rather than hypothesized treatment pathways or patterns of care derived from treatment guidelines. Yet, cost studies that capture trial-based service use and apply unit cost multipliers to reflect local circumstances may have other limitations (87) (88) (89) . Microcosting has also been used in some observational studies, particularly in countries where health coverage is applied centrally (thus, no individual billing). However, the care provided in clinical trials does not reflect typical care in community settings, including "induced costs" for some care that would not occur outside the trial setting. There are, however, processes for defining similar populations of patients, standardizing service and procedure definitions, and taking other steps to promote comparability of cost estimates across observational studies (75, 90, 91) .
Prior reviews have described methodological limitations with descriptive economic studies (12) as well as cost-effectiveness analyses (92) . We observed many of the same limitations here. Patient characteristics that influence care and costs, such as age distribution and stage of disease at diagnosis, were frequently not reported, nor were methods used to estimate costs always clearly stated. Many economic studies based on treatment trials did not report the number of patients providing data for the economic study compared with the underlying treatment trial, or reported a smaller sample in the economic study than in the treatment trial, suggesting the potential for bias in the included sample (ie, not conducted in a truly randomized population). Several studies based on multinational trials did not report the number of patients from the country of interest. Reporting of patient characteristics that influence care and costs is critical for evaluation of the study and any comparisons across studies.
We also identified a number of specific methodological concerns in the studies reviewed here, related to sample selection and representativeness, phase of care definitions, and the analysis of cost data over time. Several observational studies used diagnostic or procedure codes from health-care claims to identify patientsan approach that identifies prevalent rather than incident patients, overidentifies individuals without cancer from "rule-out" diagnostic procedures, and underidentifies patients whose cancer care lacks detailed coding or does not indicate receipt of specific procedures or treatments. Additionally, diagnostic codes may reflect metastatic rather than primary tumor sites.
Finally, we identified concerns with aspects of the cost data analysis and reporting, including omission of inflation price adjusters and inadequate (or inadequately explained) methods for handling missing, censored, or highly skewed cost data. Standards for conducting and reporting cost-effectiveness analyses have been published (78), but we were not able to identify any published standards for conducting and reporting cost analyses in observational studies. Developing standards for observational studies and encouraging adherence to existing standards for cost-effectiveness analyses will be important for future efforts (1, 93, 94) , particularly with expected increases in targeted therapies that are both more effective and more expensive than current regimens. Importantly, the methodological limitations for specific studies also constrain the comparisons that can be made between studies.
We used MEDLINE, one of the largest publications databases devoted to biomedicine and health (ie, more than 5500 journals in 39 languages), to identify studies for inclusion in our review. We then reviewed the reference lists of included studies to identify additional eligible studies. It is possible that we may have missed some other eligible studies by not using additional publications databases (eg, EMBASE), but it is unlikely that our observations of heterogeneity across studies in reporting and methods and concerns about comparability across studies would be altered by missing some studies.
In summary, we found significant heterogeneity across economic studies of CRC care, greatly limiting comparisons across countries and across data sources and patient populations within country. Of particular importance for future research is greater standardization of reporting and costing methods, increased attention to patient and caregiver time costs and lost productivity, and development of data resources that improve the quality, scope, and comparability of studies over time.
